Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.

Liang Z, Zhu J, Chen L, Xu Y, Yang Y, Hu R, Zhang W, Song Y, Lu Y, Ou N, Liu X.

Andrology. 2019 Nov 19. doi: 10.1111/andr.12731. [Epub ahead of print] Review.

PMID:
31743594
2.

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.

Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5. Review.

3.

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK.

JAMA. 2011 Dec 7;306(21):2359-66. doi: 10.1001/jama.2011.1745.

PMID:
22147380
4.

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P.

Cochrane Database Syst Rev. 2018 Oct 15;10:CD012816. doi: 10.1002/14651858.CD012816.pub2.

5.

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.

Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14.

PMID:
29037513
6.

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.

BJU Int. 2014 Dec;114(6b):E82-E89. doi: 10.1111/bju.12732. Epub 2014 Jul 27.

7.

Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.

Schmid M, Sammon JD, Reznor G, Kapoor V, Speed JM, Abdollah FA, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Sun M, Trinh QD.

BJU Int. 2016 Aug;118(2):221-9. doi: 10.1111/bju.13203. Epub 2015 Jul 22.

8.

Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.

Martín-Merino E, Johansson S, Morris T, García Rodríguez LA.

Drug Saf. 2011 Nov 1;34(11):1061-77. doi: 10.2165/11594540-000000000-00000.

PMID:
21981434
9.

Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.

Wang H, Sun X, Zhao L, Chen X, Zhao J.

J Diabetes Investig. 2016 Jul;7(4):629-36. doi: 10.1111/jdi.12472. Epub 2016 Feb 8.

10.

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators.

Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Review.

11.

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.

Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y.

PLoS One. 2014 Sep 29;9(9):e107516. doi: 10.1371/journal.pone.0107516. eCollection 2014.

12.

Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.

Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, Bianco BA, Chang P, Pompeo AC, Tobias-Machado M.

World J Urol. 2015 Sep;33(9):1281-9. doi: 10.1007/s00345-014-1439-6. Epub 2014 Nov 12. Review.

PMID:
25387877
13.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
14.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

15.

Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA.

Eur Urol. 2016 Feb;69(2):204-10. doi: 10.1016/j.eururo.2015.08.027. Epub 2015 Sep 9.

16.

Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population.

Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, Ng CF.

BJU Int. 2015 Sep;116(3):382-7. doi: 10.1111/bju.12967. Epub 2015 Mar 7.

17.

Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.

Nead KT, Sinha S, Yang DD, Nguyen PL.

Urol Oncol. 2017 Nov;35(11):664.e1-664.e9. doi: 10.1016/j.urolonc.2017.07.016. Epub 2017 Aug 10. Review.

PMID:
28803700
18.

A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.

Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, Cui C, Xu T, Yu W, Jin J.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):333-339. doi: 10.1038/pcan.2016.35. Epub 2016 Sep 6. Review.

PMID:
27595915
19.

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

Botrel TE, Clark O, Lima Pompeo AC, Horta Bretas FF, Sadi MV, Ferreira U, Borges Dos Reis R.

PLoS One. 2016 Jun 16;11(6):e0157660. doi: 10.1371/journal.pone.0157660. eCollection 2016. Review.

20.

Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.

Kassem L, Shohdy KS, Abdel-Rahman O.

Curr Med Res Opin. 2018 May;34(5):903-910. doi: 10.1080/03007995.2018.1447450. Epub 2018 Mar 27. Review.

PMID:
29490505

Supplemental Content

Support Center